20,510 Shares in Haemonetics Co. (HAE) Acquired by Chicago Equity Partners LLC

Chicago Equity Partners LLC bought a new position in shares of Haemonetics Co. (NYSE:HAE) during the 4th quarter, HoldingsChannel.com reports. The fund bought 20,510 shares of the medical instruments supplier’s stock, valued at approximately $1,191,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Amalgamated Bank boosted its position in shares of Haemonetics by 5.7% during the 2nd quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 392 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Haemonetics by 1.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 39,906 shares of the medical instruments supplier’s stock worth $1,575,000 after acquiring an additional 488 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Haemonetics by 2.7% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 28,153 shares of the medical instruments supplier’s stock worth $1,112,000 after acquiring an additional 742 shares in the last quarter. Rothschild Asset Management Inc. boosted its position in shares of Haemonetics by 1.5% during the 3rd quarter. Rothschild Asset Management Inc. now owns 89,178 shares of the medical instruments supplier’s stock worth $4,001,000 after acquiring an additional 1,320 shares in the last quarter. Finally, Cardinal Capital Management boosted its position in shares of Haemonetics by 10.0% during the 3rd quarter. Cardinal Capital Management now owns 15,029 shares of the medical instruments supplier’s stock worth $674,000 after acquiring an additional 1,363 shares in the last quarter.

In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $54.93, for a total value of $257,676.63. Following the sale, the chief accounting officer now owns 3,747 shares in the company, valued at $205,822.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronald G. Gelbman sold 5,440 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $56.69, for a total transaction of $308,393.60. The disclosure for this sale can be found here. Insiders sold 37,560 shares of company stock worth $2,133,607 in the last 90 days. Company insiders own 1.20% of the company’s stock.

Shares of Haemonetics Co. (NYSE:HAE) opened at $68.87 on Friday. Haemonetics Co. has a 52-week low of $36.83 and a 52-week high of $72.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.82 and a quick ratio of 1.51. The firm has a market cap of $3,726.90, a P/E ratio of 38.31, a price-to-earnings-growth ratio of 4.77 and a beta of 1.06.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm had revenue of $234.04 million for the quarter, compared to analyst estimates of $227.79 million. During the same quarter last year, the business posted $0.43 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. equities research analysts expect that Haemonetics Co. will post 1.87 EPS for the current fiscal year.

Haemonetics announced that its Board of Directors has authorized a share repurchase plan on Tuesday, February 6th that authorizes the company to repurchase $260.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Several analysts recently issued reports on HAE shares. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price target on the stock in a research report on Wednesday, October 25th. Barrington Research increased their price target on shares of Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. Craig Hallum reiterated a “hold” rating and set a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. Morgan Stanley increased their price target on shares of Haemonetics from $43.00 to $51.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 9th. Finally, Raymond James Financial upgraded shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $70.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2018/02/09/20510-shares-in-haemonetics-co-hae-acquired-by-chicago-equity-partners-llc.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply